ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

idelalisib

Also written as “Idelalisib”, “CAL-101” and “CAL101”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Idiopathic Pulmonary Fibrosis · Primary Myelofibrosis · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Drug pageIdelalisib: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 12, 201628 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences260 open or runningphase 4since Apr 12, 2016Jul 1, 2008none ahead
Calluna Pharma ASits history only11 open or runningphase 2since Dec 16, 2024Dec 16, 2024Nov 2026phase 2 · NCT06736990
Eli Lillyits history only11 open or runningphase 4since Oct 16, 2025Oct 16, 2025May 2030phase 4 · NCT07218341

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Jul 1, 2008.

  1. Aug 3, 2012Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01659047
  2. Aug 3, 2012Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01659021 · 261 enrolled · United States, Australia, Belgium and more
  3. Nov 14, 20122 phase 3 studies in Lymphoma, FollicularNCT01732926, NCT01732913
  4. Feb 19, 2013Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01796470 · 66 enrolled · United States
  5. Nov 5, 20132 phase 3 studies in Leukemia, Lymphocytic, Chronic, B-CellNCT01980888, NCT01980875
  6. Jan 22, 2014Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02044822 · 102 enrolled · United States, Australia, Austria and more
  7. Sep 13, 2014Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02242045 · 6 enrolled · Japan
  8. Oct 3, 2014Phase 2 study in Lymphoma, FollicularNCT02258529 · 10 enrolled · United States
  9. May 1, 2015Phase 1 study in Primary MyelofibrosisNCT02436135 · 10 enrolled · United States
  10. Jun 8, 2015Phase 1 study in RecurrenceNCT02468557 · 16 enrolled · United States
  11. Aug 27, 2015Phase 3 study in Lymphoma, FollicularNCT02536300 · 96 enrolled · Australia, Canada, Czechia and more
  12. Apr 12, 2016Phase 4 study in Lymphoid MalignanciesNCT02739360 · 3 enrolled · Netherlands
  13. Nov 16, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02968563 · 35 enrolled · Germany
  14. Nov 17, 2017Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT03349346 · France, Italy, Poland and more

TargetBeta

PIK3CD →read by rule
“An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) ”NCIt, by rule
“PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CD

ProgramCompanyFurthest phaseStudies
duvelisibruleSecuraBiophase 326
leniolisibrulePharming Groupphase 39
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24
roginolisibruleioncturaphase 24

Studies

All 26 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03349346Lymphoma, Large B-Cell, Diffuse · France, Italy, Poland and more1WithdrawnFeb 20210
NCT02968563Leukemia, Lymphocytic, Chronic, B-Cell · Germany2CompletedJun 17, 201935
NCT02739360Lymphoid Malignancies · Netherlands4TerminatedDec 28, 20173
NCT02536300Lymphoma, Follicular · Australia, Canada, Czechia and more3TerminatedSep 27, 202296
NCT02468557Recurrence · United States1TerminatedApr 27, 201616
NCT02436135Primary Myelofibrosis · United States1TerminatedNov 20, 201710
NCT02258529Lymphoma, Follicular · United States2TerminatedApr 12, 201610
NCT02242045Leukemia, Lymphocytic, Chronic, B-Cell · Japan1CompletedDec 25, 20146
NCT02044822Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more2TerminatedApr 27, 2016102
NCT01980888Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3TerminatedMay 30, 2016311
NCT01980875Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3TerminatedMay 13, 201657
NCT01796470Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedJan 201566
NCT01732926Lymphoma, Follicular · United States, Australia, Canada and more3TerminatedMay 17, 2016475
NCT01732913Lymphoma, Follicular · United States, Australia, Czechia and more3TerminatedMay 18, 2016295
NCT01659047Leukemia, Lymphocytic, Chronic, B-Cell2WithdrawnDec 20140
NCT01659021Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3TerminatedAug 15, 2018261
NCT01569295Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedJun 10, 2019416
NCT01539512Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany and more3CompletedOct 2013220
NCT01539291Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany and more3TerminatedMay 21, 2018161
NCT01393106Hodgkin Disease · United States2CompletedAug 201425
NCT01306643Lymphoma, Follicular · United States2CompletedAug 201518
NCT01282424Lymphoma, Follicular · United States, France, Germany and more2CompletedMay 2, 2018125
NCT01203930Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedAug 2015105
NCT01090414Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedJun 18, 2018202
NCT00836914Rhinitis, Allergic · Austria1CompletedMar 200941
NCT00710528Leukemia, Lymphocytic, Chronic, B-Cell · United States1CompletedDec 2011192

How it is read

Names in the registry

  • “Idelalisib”, 24 entries
  • “CAL-101”, 2 entries
  • “CAL101”, 1 entry
  • “GS-1101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.